Exhibit 99.1

FOR IMMEDIATE RELEASE

Oragenics Announces Financing Commitment

ALACHUA, FL (November 21, 2005): Oragenics, Inc. (AMEX:ONI) announced today that
it has entered into a definitive agreement for equity based financing of up to
$1.2 million from a group of individuals who are accredited investors that have
previously invested in the company. The agreement provides for the sale of up to
3,000,000 newly issued shares of common stock at a price of $0.40 per share and
the issuance of an equal number of warrants to purchase shares of common stock
that will be exercisable at $0.60 per share. The transaction is expected to
close by December 8, 2005.

As stated by Oragenics' President and CEO, Dr. Robert Zahradnik, "We anticipate
that the successful completion of this financing will provide us with the
necessary capital to move our SMaRT replacement therapy technology further along
in its clinical trial and to perform preclinical toxicology studies to enable us
to apply for an IND ("Investigation New Drug") application by mid 2006 with our
MU 1140 antibiotic technology."

Neither the shares of common stock, nor the shares of common stock underlying
the warrants are registered under the Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. However, the company will
be obligated to file a resale registration statement with the Securities and
Exchange Commission relating to the shares of common stock to be issued in the
transaction and the shares of common stock to be issued upon exercise of the
warrants within forty five days of the closing. Oragenics plans to use the funds
raised to support the clinical development of the company's various technologies
and for general corporate purposes.

Oragenics also has amended its bank loan agreement whereby the company has
deposited an amount equal to the remaining principal balance due of
approximately $305,000 into a restricted account and the funds will not be
available to the company for working capital. The bank has also removed various
financial covenants from the terms of the agreement.

About Oragenics

Oragenics is focused on the development of novel technologies and products to
address significant, unmet medical needs. Oragenics' strategy is to license and
develop products through human proof-of-concept studies prior to partnering with
major pharmaceutical, biotechnology or healthcare product firms for advanced
clinical development and commercialization. Upon completion of the private
placement financing Oragenics plans to continue its development of the following
products, which address potentially major market opportunities:

      o     SMaRT Replacement Therapy is a single, painless topical treatment
            that has the potential to offer life-long protection from most tooth
            decay.

      o     MU 1140 is a novel antibiotic with activity against many
            Gram-positive bacteria including multidrug resistant Staphylococcus
            aureus and Enterococcus faecalis. MU 1140 has a number



            of other characteristics that suggest its potential use in the
            treatment of a variety of infectious diseases.

For more information about Oragenics, please consult the company's website at
www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to our
ability to successfully close on the above described private placement, those
set forth in our most recently filed annual report on Form 10-KSB and quarterly
report on Form 10-QSB, and other factors detailed from time to time in filings
with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.

- ------------------------
Contact:
Contact:
     Oragenics, Inc.
     Paul A. Hassie, 386-418-4018 X232
     www.oragenics.com
     -----------------
     or
     Investor Awareness, Inc.
     Tony Schor, 847-945-2222
     www.investorawareness.com
     -------------------------


                                  #   #   #